De novo drug design based on patient gene expression profiles via deep learning

Abstract excerpt

Computational de novo drug design is a challenging issue in medicine, and it is desirable to consider all of the relevant information of the biological systems in a disease state. Here, we propose a novel computational method to generate drug candidate molecular structures from patient gene expression profiles via deep learning, which we call DRAGONET. Our model can generate new molecules that are likely to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Computational Drug Discovery Methods
• Share to Microbial Natural Products and Biosynthesis
• Share to vaccines and immunoinformatics approaches